Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals. Telix’s …

Telix Completes Acquisition of FAP-targeting Theranostic Candidates. ASX, News, Telix today announces that it has completed the transaction to expand its theranostic pipeline with new …

Telix is focused on developing therapies for urologic (prostate and kidney), neurologic (brain) and musculoskeletal (sarcoma) cancers. The Precision Medicine unit support the Therapeutics unit …

Telix is developing targeted radiation therapies with the potential to be efficacious as stand-alone treatments or as complements to existing treatment modalities, addressing areas of high …

At Telix we believe that everyone counts, we strive to be extraordinary, and we pursue our goals with determination and integrity every day

Telix will leverage RLS’ 31 licensed radiopharmacies located in major metropolitan areas across the U.S. to build a radiometal production and distribution network for key therapeutic and …

Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals.

Telix is actively exploring partnership opportunities for our programs and platforms. Please contact us to find out more..

Telix is pushing the frontiers of diagnostic and therapeutic nuclear medicine through a number of clinical trials, both company-sponsored and in collaboration with leading cancer centres …

2025年1月13日 · Strong sales of Illuccix have led Telix to close out the year with revenue above guidance, while significantly progressing our strategic priorities. Boosting our balance sheet …